Literature DB >> 9424982

Competing practice guidelines: using cost-effectiveness analysis to make optimal decisions.

A V Granata1, A L Hillman.   

Abstract

In this paper, cost and effectiveness data for six clinical interventions are applied simultaneously to a hypothetical population of 100,000 patients to show how selecting guidelines to maximize overall population benefit compares with selecting the best guidelines for individual patients. By entering effectiveness (added survival) and cost information from recent prevention, screening, diagnostic, and therapeutic guidelines into a computer-based optimization model, the options that maximized overall population effectiveness while keeping additional cost within varying specified constraints were identified. In 57% of selection opportunities, the clusters of guidelines that yielded maximum population benefit differed from those that maximized benefit for individual patients. Some choices were more stable than others over ranges of cost constraints. Clinical practice guidelines chosen to maximize cost-effectiveness for individual patients often do not maximize cost-effectiveness for populations of patients. To allocate resources as efficiently as possible, decision makers should consider other sources of information in addition to the recommendations of specific practice guidelines. "Robust" guidelines that simultaneously address both individual and societal health benefit should be sought.

Entities:  

Mesh:

Year:  1998        PMID: 9424982     DOI: 10.7326/0003-4819-128-1-199801010-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  14 in total

1.  Guidelines for appropriate care: the importance of empirical normative analysis.

Authors:  M Berg; R T Meulen; M van den Burg
Journal:  Health Care Anal       Date:  2001

2.  Integer/linear mathematical programming models: a tool for allocating healthcare resources.

Authors:  Stephanie R Earnshaw; Susan L Dennett
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 3.  Ethical issues of cost effectiveness analysis and guideline setting in mental health care.

Authors:  R Berghmans; M Berg; M van den Burg; R ter Meulen
Journal:  J Med Ethics       Date:  2004-04       Impact factor: 2.903

4.  Reflections of the Hippocratic Oath in modern medicine.

Authors:  Stavros A Antoniou; George A Antoniou; Frank A Granderath; Anna Mavroforou; Athanasios D Giannoukas; Athanasios I Antoniou
Journal:  World J Surg       Date:  2010-12       Impact factor: 3.352

Review 5.  Bias in published cost effectiveness studies: systematic review.

Authors:  Chaim M Bell; David R Urbach; Joel G Ray; Ahmed Bayoumi; Allison B Rosen; Dan Greenberg; Peter J Neumann
Journal:  BMJ       Date:  2006-02-22

6.  Using decision theory to derive optimal cut-off scores of screening instruments: an illustration explicating costs and benefits of mental health screening.

Authors:  Niels Smits; Filip Smit; Pim Cuijpers; Ron De Graaf
Journal:  Int J Methods Psychiatr Res       Date:  2007       Impact factor: 4.035

Review 7.  The unintended consequences of quality improvement.

Authors:  Naomi S Bardach; Michael D Cabana
Journal:  Curr Opin Pediatr       Date:  2009-12       Impact factor: 2.856

8.  When there is too much to do: how practicing physicians prioritize among recommended interventions.

Authors:  Timothy P Hofer; Judith K Zemencuk; Rodney A Hayward
Journal:  J Gen Intern Med       Date:  2004-06       Impact factor: 5.128

9.  Beyond comorbidity counts: how do comorbidity type and severity influence diabetes patients' treatment priorities and self-management?

Authors:  Eve A Kerr; Michele Heisler; Sarah L Krein; Mohammed Kabeto; Kenneth M Langa; David Weir; John D Piette
Journal:  J Gen Intern Med       Date:  2007-07-24       Impact factor: 5.128

10.  Recommendations for increasing the use of HIV/AIDS resource allocation models.

Authors:  Arielle Lasry; Anke Richter; Frithjof Lutscher
Journal:  BMC Public Health       Date:  2009-11-18       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.